<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HB074B3C396134F3ABAE04730BBDC31A3" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 383 IH: To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-01-17</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 383</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230117">January 17, 2023</action-date><action-desc><sponsor name-id="H001086">Mrs. Harshbarger</sponsor> (for herself, <cosponsor name-id="H001082">Mr. Hern</cosponsor>, <cosponsor name-id="L000564">Mr. Lamborn</cosponsor>, <cosponsor name-id="B001307">Mr. Baird</cosponsor>, <cosponsor name-id="C001103">Mr. Carter of Georgia</cosponsor>, <cosponsor name-id="W000814">Mr. Weber of Texas</cosponsor>, <cosponsor name-id="M001211">Mrs. Miller of Illinois</cosponsor>, <cosponsor name-id="B001299">Mr. Banks</cosponsor>, <cosponsor name-id="J000304">Mr. Jackson of Texas</cosponsor>, <cosponsor name-id="W000806">Mr. Webster of Florida</cosponsor>, <cosponsor name-id="D000615">Mr. Duncan</cosponsor>, <cosponsor name-id="F000446">Mr. Feenstra</cosponsor>, <cosponsor name-id="S000522">Mr. Smith of New Jersey</cosponsor>, and <cosponsor name-id="G000565">Mr. Gosar</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.</official-title></form><legis-body id="H1D9BE82797CA46B7903EB19987804405" style="OLC"> 
<section id="HDE2953E6B09643B4AB61C25B8A3A5462" section-type="section-one"><enum>1.</enum><header>Nullification of modifications to REMS for mifepristone</header> 
<subsection id="H5603E4852CBD44988EB7F6BB75E8C7DA"><enum>(a)</enum><header>Nullification</header><text display-inline="yes-display-inline">The modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1</external-xref>) for mifepristone are hereby nullified.</text></subsection> <subsection id="H61740E6CC2B948CDBFE5D81C6BBDC37C"><enum>(b)</enum><header>No substantially similar provisions</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services (or any head of any office, department, or agency of the Department of Health and Human Services) shall not establish, implement, or enforce any provision of a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1</external-xref>) for mifepristone that is substantially similar to any of the modifications nullified by subsection (a).</text></subsection></section> 
</legis-body></bill>


